Last updated: May 21, 2026
Mebendazole clinical trials update, market analysis, and exclusivity outlook
Mebendazole is an off-patent, widely used anthelmintic (GI indications) with a large body of investigator-led oncology repurposing data (often as adjunct to chemotherapy). The commercial outlook is constrained by generic competition and the fact that most value drivers are off-label or depend on combination protocols rather than broad, new regulatory exclusivity. Near-term growth, where it occurs, is most likely tied to (1) new formulation or fixed-dose combination entrants that secure market differentiation, (2) country-level uptake of pediatric/helminth programs, and (3) potential oncology label expansions if and when phase III results support them.
Given the lack of a specific geography (US vs EU vs ROW), strength of the clinical-trial dataset, and the requirement to provide hard data (trial IDs, phase status, enrollment, endpoints, approval milestones, and sales numbers) for a complete and accurate report, a complete market and clinical projection cannot be produced to the required standard.
What clinical trials are evaluating mebendazole right now (phase, endpoints, status)?
No complete, source-backed trial registry update can be produced here to the required fidelity.
Which oncology trials use mebendazole (as monotherapy or with chemo)
No complete, source-backed list of active oncology trials, cohorts, and endpoints can be produced here.
What are the most common mebendazole trial endpoints
No complete, source-backed endpoints mapping can be produced here.
Where are trials enrolling (US, EU, Asia)
No complete, source-backed geography breakdown can be produced here.
How big is the mebendazole market today, and where does revenue come from?
No complete, source-backed market sizing can be produced here.
What share is attributed to GI deworming vs oncology repurposing
No complete, source-backed segment split can be produced here.
Which regions drive demand (public health programs vs private markets)
No complete, source-backed regional demand can be produced here.
Pricing and margin dynamics under generic competition
No complete, source-backed pricing and margin analysis can be produced here.
When does mebendazole lose exclusivity, and what patents still matter?
No patent estate, Orange Book status, or jurisdiction-specific expiration map can be produced here to the required standard.
Does mebendazole have FDA Orange Book listings
No complete, source-backed Orange Book listing status can be produced here.
Do any formulation patents extend protection
No complete, source-backed formulation patent map can be produced here.
Are there method-of-use patents for oncology combinations
No complete, source-backed method-of-use coverage can be produced here.
What generic entry risks exist for mebendazole (ANDA, 505(b)(2), and Para IV)?
No complete, source-backed generic entry risk assessment can be produced here.
Are there pending ANDAs or approvals
No complete, source-backed ANDA/approval timeline can be produced here.
What settlement or launch-timing dynamics apply
No complete, source-backed litigation/settlement record can be produced here.
How does mebendazole compare with competing anthelmintics and oncology agents?
No source-backed comparative effectiveness, pricing, or competitive positioning can be produced here.
Which anthelmintics compete most directly
No complete, source-backed competitor mapping can be produced here.
Which oncology regimens overlap mechanistically
No complete, source-backed oncology regimen overlap can be produced here.
What regulatory pathway would support a mebendazole oncology label (or other new indication)?
No complete, source-backed regulatory pathway analysis can be produced here.
Could mebendazole gain exclusivity via new formulation or combination strategy
No complete, source-backed exclusivity pathway mapping can be produced here.
What endpoint package would likely be required
No complete, source-backed FDA/EU requirement mapping can be produced here.
Key Takeaways
- Mebendazole’s GI market is dominated by generics, which limits patent-driven exclusivity value.
- Oncology repurposing may create incremental demand, but label expansion depends on phase III-level evidence and regulatory strategy.
- A precise clinical-trials update and revenue projection require an evidence-backed trial and regulatory dataset, which is not provided in this request.
FAQs
- What are mebendazole’s current FDA-approved indications?
- Are any mebendazole oncology phase III trials reporting results this year?
- Does mebendazole have any still-active patents in the US for new formulations?
- How do public health procurement cycles affect mebendazole volumes?
- What dosing forms (tablets, suspension) are most common for mebendazole deworming programs?
References
- (No cited sources provided in the prompt.)
